TL;DR: Hyperbaric oxygen therapy (HBOT) is emerging as a candidate intervention for Alzheimer’s disease and vascular dementia. A 2024 meta-analysis of 11 randomised controlled trials (n=847) reported significant improvements in MMSE, ADAS-Cog, and activities of daily living scores, with no serious adverse events. Preclinical work in 2025 has clarified HBOT’s effect on amyloid clearance, mitophagy, and neuroinflammation. The evidence base remains small, heterogeneous, and dominated by trials conducted in China, so Canadian researchers have a clear opportunity to contribute larger, well-designed RCTs.
What is hyperbaric oxygen therapy, and why is it being studied for Alzheimer’s disease?
Hyperbaric oxygen therapy is a medical treatment in which a patient breathes 100% oxygen inside a pressurised chamber, typically at 1.5 to 2.5 atmospheres absolute (ATA). The combination of pressure and pure oxygen increases plasma-dissolved oxygen delivery to hypoxic tissues by a factor of 10 or more. In Canada, HBOT is regulated by Health Canada under the Medical Devices Regulations and is delivered in hospitals and regulated facilities across the country.
Researcher interest in HBOT for Alzheimer’s disease stems from a straightforward observation. Chronic cerebral hypoxia is now recognised as an upstream driver of Alzheimer’s pathology. It aggravates amyloid-beta (Aβ) deposition, tau phosphorylation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. A 2023 review in Redox Biology framed this as a vicious cycle in which hypoxia and oxidative stress reinforce each other (Liu et al., 2023, DOI: 10.1016/j.redox.2023.102955). HBOT directly targets the hypoxia limb of this cycle, and that is the biological rationale the current trials are testing.
What does the clinical evidence show for HBOT in Alzheimer’s disease?
The most rigorous synthesis to date is a 2024 systematic review and meta-analysis in Frontiers in Aging Neuroscience. Lin and colleagues searched nine databases through November 2023 and pooled data from 11 randomised controlled trials enrolling 847 participants (Lin et al., 2024, DOI: 10.3389/fnagi.2024.1360148).
The pooled effects were large and consistent:
| Outcome | Pooled Effect | 95% CI | p-value |
|---|---|---|---|
| MMSE (cognition) | MD +3.08 | 2.56 to 3.61 | <0.00001 |
| ADAS-Cog (cognitive assessment) | MD -4.53 | -5.05 to -4.00 | <0.00001 |
| ADL (daily living) | MD +10.12 | 4.46 to 15.79 | 0.0005 |
| Adverse events | OR 1.17 | 0.68 to 2.03 | 0.58 (n.s.) |
The review also pooled biochemical markers. HBOT was associated with lower malondialdehyde (MDA) and interleukin-1β concentrations, and higher superoxide dismutase (SOD) and transforming growth factor-β1 (TGF-β1) levels. Those findings support an oxidative stress and neuroinflammatory mechanism rather than a placebo effect on rating scales alone. Sensitivity analyses confirmed the pooled estimates were robust.
A separate 2025 systematic review of HBOT for long-COVID cognitive decline, which overlaps with the Alzheimer’s mechanistic hypothesis through chronic cerebral hypoperfusion, reported improvements in memory, executive function, attention, and fatigue across seven studies (Zamora et al., 2025, PMID 41223394). And a 2025 meta-analysis of 13 RCTs in Parkinson’s disease patients (n=958) found HBOT improved UPDRS III motor scores alongside MoCA cognition, suggesting the cognitive effect is not specific to AD pathology (Bu et al., 2025, DOI: 10.1159/000542619).
What does preclinical research reveal about HBOT mechanisms in dementia?
Three 2025 animal studies have added mechanistic depth to the clinical signal.
Amyloid clearance and mitophagy. Yao and colleagues treated 5xFAD transgenic mice with HBOT and tracked them using longitudinal AV-45 PET-MR imaging. They reported progressive reductions in amyloid tracer uptake, lower histological plaque burden, and upregulation of LRP1, a key Aβ clearance transporter. Treated mice also showed enhanced PINK1 and parkin expression, indicating improved mitochondrial quality control, and microglial transition toward a surveillance phenotype (Yao et al., 2025, DOI: 10.1016/j.expneurol.2025.115534). The authors concluded that HBOT may be most effective at early stages of disease, when amyloid clearance remains responsive.
Autophagy signalling. Li and colleagues studied APP/PS1 double transgenic mice and found HBOT significantly upregulated five autophagy-associated genes (Tgfb1, Mapk14, Bid, Atg7, and Akt1) in the hippocampus, alongside improved Morris water maze performance (Li et al., 2025, DOI: 10.33549/physiolres.935447). Autophagy dysregulation is a core feature of AD, and these genes are plausible effectors of HBOT’s cognitive benefit.
Vascular cognitive impairment. Yang and colleagues modelled chronic cerebral hypoperfusion in mice and identified a distinct microRNA pathway (miR-137-3p/TRAF3) that HBOT upregulates. Activation of this pathway suppressed the TAK1/NF-κB inflammatory cascade and reduced neuronal apoptosis (Yang et al., 2025, DOI: 10.1038/s41398-025-03771-z). Vascular cognitive impairment is the second-most-common dementia type in Canada and has no approved pharmacotherapy, which makes this target clinically relevant.
What pressure and session protocols have been used in HBOT dementia trials?
Protocol heterogeneity is one of the main limitations of the current evidence. Across the 11 RCTs pooled in the 2024 meta-analysis, treatment pressures ranged from 1.5 to 2.5 ATA, session durations from 60 to 90 minutes, and total session counts from 20 to 60. A 2025 dose-effect study in an amnestic mild cognitive impairment rat model compared six pressures from 1.6 to 2.8 ATA and concluded that 2.0 ATA for 60 minutes per day over five days produced the best cognitive outcomes and the most favourable oxidative stress profile (Chen et al., 2025, DOI: 10.1159/000545906).
The practical protocol elements that matter for trial design include:
- Treatment pressure. Most positive trials clustered between 2.0 and 2.4 ATA. Below 1.5 ATA, the dissolved oxygen dose is likely insufficient. Above 2.5 ATA, oxygen toxicity risk rises without added benefit.
- Session duration. Typically 60 to 90 minutes at target pressure, with air breaks to reduce oxygen toxicity risk.
- Total sessions. Cognitive endpoints usually require at least 40 sessions over eight to twelve weeks.
- Disease stage. Preclinical work suggests early-stage intervention, when amyloid clearance machinery is intact, may be more productive than late-stage rescue.
- Outcome measurement. MMSE and ADAS-Cog are standard; biomarker panels (Aβ42/40, phosphorylated tau, neurofilament light) would strengthen mechanistic inference.
How does HBOT compare across different forms of cognitive impairment?
HBOT is being studied across a spectrum of cognitive conditions. The evidence strength and mechanism differ by indication.
| Condition | Evidence Level | Primary Mechanism Hypothesised |
|---|---|---|
| Alzheimer’s disease | 11 RCTs, one meta-analysis (2024) | Amyloid clearance, neuroinflammation, mitophagy |
| Vascular cognitive impairment | Preclinical + small clinical | Cerebral perfusion, miR-137-3p/TRAF3 pathway |
| Long-COVID cognitive decline | Seven studies, systematic review (2025) | Cerebral perfusion, cortical excitability |
| Parkinson’s cognition | 13 RCTs, meta-analysis (2024) | Oxidative stress, anti-apoptotic effects |
| Amnestic MCI | Dose-effect animal study (2025) | Oxidative stress reduction at 2.0 ATA |
The common thread across indications is cerebral hypoxia and oxidative stress. This convergence strengthens the biological plausibility of HBOT as a cross-cutting intervention for neurodegenerative cognitive decline. For a broader view of neurocognitive HBOT research, see the Canada Hyperbarics research library, which indexes over 14,000 HBOT studies across all indications.
What are the main limitations of the current HBOT evidence base for dementia?
Honest appraisal of the evidence requires acknowledging several limitations.
Geographic concentration. Nearly all 11 RCTs in the Lin meta-analysis were conducted in China, often in single centres with small sample sizes. Generalisability to Canadian populations, health systems, and comorbidity profiles is unclear.
Risk of bias. Blinding of a pressurised chamber intervention is notoriously difficult. Several included trials were assessed at high risk of performance bias, and sham-controlled data at ambient-pressure air or low-pressure oxygen are limited.
Heterogeneity. Pressure, duration, and session count varied widely, yet the pooled effect sizes were large and consistent. This is unusual and may reflect selective reporting.
Outcome durability. Most trials followed participants for only the treatment period or a short post-treatment window. Durability of cognitive gains beyond six months is poorly characterised.
Biomarker correlation. Few clinical studies reported fluid or imaging biomarkers. Without Aβ42/40 ratios, phospho-tau, neurofilament light, or amyloid PET data, the mechanistic translation from preclinical findings to human outcomes remains speculative.
What is the regulatory status of HBOT for Alzheimer’s disease in Canada?
Alzheimer’s disease is not among Health Canada-recognised conditions, and it is not on the Undersea and Hyperbaric Medical Society’s list of 15 recognised conditions. The Canadian Undersea and Hyperbaric Medical Association (CUHMA) treats it as an investigational indication. Any Canadian clinical trial would require Health Canada authorisation, Research Ethics Board approval, and adherence to Good Clinical Practice standards. Off-label delivery of HBOT for AD outside a research setting raises regulatory and ethical concerns and is not recommended.
Where should Canadian research on HBOT for dementia go next?
Canada has structural advantages for advancing this research area. The country has a mature network of hospital-based hyperbaric units, an engaged clinical research community in dementia (the Canadian Consortium on Neurodegeneration in Aging), and publicly funded health data that enable long-term follow-up. Priority trial designs include:
- Sham-controlled, double-blind RCTs at the protocol dose suggested by preclinical work (2.0 ATA, 60 minutes, 40-60 sessions)
- Biomarker-enriched cohorts using plasma phospho-tau 217 and amyloid PET to stratify participants by disease stage
- Early-stage focus on mild cognitive impairment and preclinical AD, where preclinical data suggest the amyloid clearance window is open
- Vascular dementia subcohorts given the distinct miR-137-3p/TRAF3 mechanism and the absence of approved therapy
- Canadian-specific cost-effectiveness analyses integrated with provincial health data
Frequently asked questions
Is HBOT a proven treatment for Alzheimer’s disease in 2026?
No. HBOT is an investigational intervention for Alzheimer’s disease. Early meta-analytic signals are encouraging but the evidence base is small, geographically concentrated, and heterogeneous. HBOT is not approved by Health Canada for AD.
What pressure is used in HBOT trials for Alzheimer’s disease?
Most positive trials used 2.0 to 2.4 ATA for 60 to 90 minutes, typically over 40 or more sessions. A 2025 dose-effect animal study identified 2.0 ATA for 60 minutes as the most effective protocol for amnestic mild cognitive impairment.
Does HBOT reduce amyloid plaques in Alzheimer’s disease models?
Preclinical evidence in 5xFAD transgenic mice shows progressive reduction in amyloid tracer uptake on PET imaging and lower histological plaque burden after HBOT, alongside upregulation of LRP1, a key Aβ clearance transporter. Human imaging evidence is limited.
How does HBOT compare to currently approved Alzheimer’s therapies?
Direct head-to-head trials against lecanemab, donanemab, or cholinesterase inhibitors have not been conducted. HBOT targets upstream hypoxia and oxidative stress rather than directly clearing amyloid through immunotherapy. Combination-therapy trials have been proposed but not published.
What adverse events are reported in HBOT dementia trials?
The 2024 meta-analysis reported no significant difference in adverse events between HBOT and control arms (OR 1.17, 95% CI 0.68 to 2.03). The most common HBOT-specific risks in general practice are middle ear barotrauma, transient myopia, and, rarely, oxygen toxicity seizures.
Is HBOT covered by provincial health plans for Alzheimer’s disease?
No Canadian provincial health plan currently covers HBOT for Alzheimer’s disease. HBOT coverage is restricted to Health Canada-recognised conditions such as decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, and a defined list of other conditions. Patients in research trials generally receive treatment at no cost within the study protocol.
Are there Canadian HBOT trials for dementia currently recruiting?
As of April 2026, no Health Canada-authorised Phase III trials of HBOT specifically for Alzheimer’s disease are listed as recruiting in Canada. Several investigator-initiated pilot studies are underway at academic hyperbaric units. Researchers interested in the area should consult ClinicalTrials.gov and provincial clinical trial registries.
Where can patients learn about HBOT services in Canada?
Canada Hyperbarics maintains a directory of verified hospitals and regulated facilities offering HBOT across every province. Patients should consult their physician about any proposed use of HBOT outside recognised indications.
Key takeaways for researchers
The 2024 meta-analysis of 11 RCTs in Alzheimer’s disease is the current high-water mark for HBOT dementia evidence, supported by consistent 2025 preclinical mechanistic findings on amyloid clearance, mitophagy, and the miR-137-3p/TRAF3 pathway. The clinical signal is real, but the evidence base needs larger, sham-controlled, biomarker-enriched, Canadian-led trials to move HBOT from promising to proven. Canada Hyperbarics will continue to index new studies on the research library as they are published.
Call to action: Researchers and clinicians interested in the evidence base across all HBOT indications can browse the full Canada Hyperbarics research library at canadahyperbarics.ca/research, or review verified Canadian HBOT hospitals and regulated facilities by province.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. Canada Hyperbarics provides editorial content about hyperbaric oxygen therapy research and access in Canada; we do not provide medical services and have no financial interest in any specific clinic.